Review

In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update

Thangavelu Soundara Rajan 1,2, Agnese Gugliandolo 3, Placido Bramanti 3 and Emanuela Mazzon 3,*

1 Department of Biotechnology, School of Life Sciences, Karpagam Academy of Higher Education, Coimbatore 641021, India; tsrajanpillai@gmail.com
2 Karpagam Cancer Research Centre, Karpagam Academy of Higher Education, Coimbatore 641021, India
3 IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Palermo, Contrada Casazza–S.S.113, 98124 Messina, Italy; agnese.gugliandolo@irccsme.it (A.G.); placido.bramanti@irccsme.it (P.B.)
* Correspondence: emanuela.mazzon@irccsme.it; Tel.: +39-090-60128172

Received: 19 June 2020; Accepted: 4 September 2020; Published: 6 September 2020

Abstract: Adoptive T cell immunotherapy has received considerable interest in the treatment of cancer. In recent years, chimeric antigen receptor T cell (CAR T) therapy has emerged as a promising therapy in cancer treatment. In CAR T therapy, T cells from the patients are collected, reprogrammed genetically against tumor antigens, and reintroduced into the patients to trigger an immense immune response against cancer cells. CAR T therapy is successful in hematologic malignancies; however, in solid tumors, CAR T therapy faces multiple challenges, including the on-target off-tumor phenomenon, as most of the tumor-associated antigens are expressed in normal cells as well. Consequently, a transient in vitro-transcribed anti-mRNA-based CAR T cell (IVT mRNA CAR T) approach has been investigated to produce controlled cytotoxicity for a limited duration to avoid any undesirable effects in patients. In vitro and in vivo studies demonstrated the therapeutic ability of mRNA-engineered T cells in solid tumors, including melanoma, neuroblastoma and ovarian cancer; however, very few clinical trials are registered. In the present review, we discuss the effect of IVT mRNA CAR T therapy in preclinical studies related to hematologic malignancies and solid tumor management. In addition, we discuss the clinical trial studies based on IVT mRNA CAR T therapy in cancer.

Keywords: adoptive T cell immunotherapy; chimeric antigen receptor; in vitro-transcribed mRNA; T cells; hematologic tumors; solid tumors

1. Introduction

In recent years, adoptive T cell immunotherapy has emerged as a promising therapy for cancer patients. It is based on two methods: (i) to isolate the tumor-infiltrating lymphocytes from the primary tumor tissues of patients [1] and (ii) to construct T cells with defined specificity against tumor antigens using gene modification approaches [2]. Two gene modification approaches have been used to manufacture the monoclonal T cells with predetermined antigen specificity, namely T cell receptor (TCR) gene transfer and chimeric antigen receptor (CAR) gene transfer [2]. CAR T (CAR T) cells have received significant attention as the most promising adoptive immunotherapy for cancer. CAR T cells are genetically reprogrammed to express an antigen-specific, non-MHC-restricted receptor. This receptor is composed of the extracellular antigen recognition domain, which is most commonly

Int. J. Mol. Sci. 2020, 21, 6514; doi:10.3390/ijms21186514 www.mdpi.com/journal/ijms
CAR T therapy is successful in hematologic malignancies, for example, B cell malignancies, which include acute lymphoblastic leukemia, chronic lymphoblastic leukemia and non-Hodgkin lymphoma [5]. However, in solid tumors, CAR T therapy faces multiple challenges, with limited success. For example, unlike hematologic malignancies, finding an ideal single target antigen is more difficult in solid tumors. On the other hand, it is more common to detect a tumor-associated antigen(s) (TAA) in a solid tumor. TAAs are overexpressed in tumors but also expressed at the physiological level in normal non-tumor tissues. Proteins such as epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), epidermal growth factor receptor 2 (ERBB2), prostate-specific membrane antigen (PSMA) and mesothelin are examples of frequently targeted TAAs present in solid tumors [6]. Indeed, a lack of tumor antigen specificity of CAR T cells enhances the risk of substantial on-target off-tumor toxicity in normal tissues, which occurs when the indefinite period of CAR expression in T cells attacks non-tumor cells that display the intended antigens. This is one of the clinical challenges in the conventional CAR T therapy in cancer treatment. Other challenges include a lack of knowledge of appropriate tumor specific antigen(s) (TSAs)/TAAs, heterogeneity of tumor antigens, difficulties of CAR T cells to enter into tumor sites and the negative effect of the tumor microenvironment on CAR T cells [7]. In order to circumvent on-target off-tumor toxicity, in vitro transcribed mRNA CAR T (IVT mRNA CAR T) cells are emerging as a safe therapeutic approach, where T cells are transiently reprogrammed with mRNA that encodes chimeric membrane antigen receptor protein against a TSA or TAA. Due to the labile nature of mRNA, IVT-mRNA CAR T reduces the side effects associated with on-target off-tumor toxicity [8]. However, there are limitations associated with the IVT mRNA approach, which include a lack of sufficient longevity of mRNA-redirec ted T cells, which results in the expression of encoded protein for a few days, poor tumor infiltration, manufacturing challenges when a limited quantity of T cells are available and the risk of side effects when repeated doses of CAR T cells are injected. The scheme of IVT mRNA CAR T therapy in cancer patients is shown in Figure 1.

**Figure 1.** The scheme of IVT mRNA CAR T therapy in cancer patients. IVT mRNA CAR T: in vitro transcribed mRNA chimeric antigen receptor T cells; TSA: Tumor-specific antigen; TAA: Tumor-associated antigen.
In the present review, we discuss the preclinical reports on the effect of IVT mRNA CAR T in hematologic and solid malignancies. Furthermore, we discuss the clinical trial studies based on IVT mRNA CAR T therapy in cancer. In order to collect research articles related to IVT mRNA CAR T therapy, we performed PubMed and Google Scholar searches using the following key words: “In vitro transcribed mRNA chimeric antigen receptor T cells and cancer”, “IVT- mRNA CAR T and cancer”, “In vitro mRNA CAR T and cancer”, “In vitro mRNA CAR T and hematologic tumors”, “In vitro mRNA CAR T and leukemia”, “In vitro mRNA CAR T and lymphoma”, “In vitro mRNA CAR T and solid tumors”, and “In vitro mRNA CAR T and cancer and case reports”.

2. Effect of IVT mRNA CAR T Cells in Preclinical Studies Related to Hematologic Malignancies

2.1. Chronic Lymphocytic Leukemia (CLL)

CLL is a type of cancer, characterized by excessive production of lymphocytes by bone marrow in a slow progressive manner [9]. The CD19 surface antigen marker has been investigated in many studies of IVT mRNA CAR T against CLL. In a primitive in vitro study, Rabinovich et al. demonstrated the cytotoxic efficacy of human chimeric immune receptor T cells modified with mRNA which targeted B cell surface antigen CD19. This antigen is expressed in normal B cells and B cell-derived malignancies [10]. Moreover, the same group reported the killing ability of CD19-targeted mRNA-expressing human CD3+CD8+ cells in a humanized mouse model of Daudi lymphoma [11].

In another study, CD19-targeting mRNA in T lymphocytes collected from leukemia and lymphoma patients were investigated against B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) cells [12]. Degranulation and secretion of IFN-γ were noticed upon the recognition of CD19 in B-CLL and MCL cells. Moreover, in this study, CXCR4 or CCR7 mRNA was co-transfected together with CD19 mRNA to enhance the chemotactic response of the CAR T cells. Of note, in certain cancers, T cells may not reach the tumor site. Accordingly, insertion of CXCR4 or CCR7 mRNA contributes to the homing of CAR T cells towards bone marrow and lymphnodes, respectively, and binding with CD19 surface antigen. Köksal et al. demonstrated the killing efficiency and/or tumor growth in vitro and in vivo of CD37-targeting mRNA CAR T cells against human Burkitt’s lymphoma cell line BL41 and diffuse large B cell lymphoma cell line U-2932 [13]. In addition to murine models, the feasibility and safety of IVT mRNA CAR T cells has been investigated in canine models. Canine CD20-ζ mRNA CAR T cells induced modest antitumor activity in a dog with relapsed B cell lymphoma [14].

2.2. Acute Lymphoblastic Leukemia (ALL)

ALL is a type of cancer where the rapid progression of lymphocyte multiplication occurs in bone marrow. It is the most common childhood cancer [9]. As in CLL, CD19 is the most investigated tumor antigen for IVT mRNA CAR T cells versus ALL. Barrett et al. showed the cytotoxic potential of human CD19 mRNA-redirected T cells against the Nalm-6 human ALL cell line and K562 human erythroleukemic cell line engineered to express the CD19 antigen [15]. In the same study, similar killing potential of CD19-targeted CAR T cells was observed in a humanized mouse ALL model generated by Nalm-6 xenografting. In 2013, the same group examined the impact of regimen-based repeated infusions of CD19-targeted mRNA CAR T cells in a mouse Nalm-6–ALL xenograft model [16]. They suggested that the split dosage of mRNA-engineered CAR T cells and the timing of lymphodepletion serve a major role in enhancing the degree of the anti-leukemic effect of CD19-targeted mRNA CAR T cells.

Almåsbak et al. documented the possible role of the non-signaling constituents present in CAR constructs [17]. They observed that the presence of a IgG1-CH2CH3 spacer in the CD19-targeted mRNA CAR construct inhibited the cytotoxic efficacy of the reprogrammed CAR T cells in a mouse Nalm-6–ALL xenograft model. Interestingly, the authors found CD19-independent severe toxicity in ALL mice. Further analyses revealed that the observed CD19-independent toxicity was attributed to the binding of the IgG1-CH2 spacer domain (which contains fragment c gamma receptor (FcγR)-binding
motifs) of the CAR construct with soluble FcγR-1 of the macrophages of ALL mice, which caused off-target CAR T cell activation towards the mouse macrophages. Findings from this study highlighted the importance of the spacer in CAR constructs in clinical settings. Although these preclinical results seem to discourage the use of an IgG-derived hinge, the impact in a human clinical setting requires further investigation [18,19].

2.3. Acute Myeloid Leukemia (AML)

AML is a type of cancer with the rapid progression of myeloid cell multiplication in bone marrow [9]. CD33 and CD123 are the surface markers investigated for IVT mRNA CAR T cells in AML treatment [20]. Kenderian et al. designed CAR T cells with CD33-targeting mRNA and investigated their cytotoxic ability in in vitro and in vivo models of AML [21]. Specific cell death and loss of leukemia burden were noticed in the IVT CAR CD33 mRNA-treated human MOLM14 cell line and in a humanized mouse AML model xenografted with MOLM14 cells, respectively. In this study, CD33 mRNA-reprogrammed CAR T cells were administered with cyclophosphamide, an immunosuppressant drug, which augmented the persistence of the CAR T cells. In 2017, the same group documented the cytotoxic effect of CD123-targeted mRNA-engineered human CAR T cells in a humanized mouse AML model [22].

An overview of the results obtained in preclinical studies related to hematologic malignancies is shown in Table 1.

### Table 1. Preclinical studies regarding the effects of IVT mRNA CAR T cells in hematologic malignancies

| Type of Study | Target | Dose and Administration | Tumor Type | Results | Reference |
|---------------|--------|-------------------------|------------|---------|-----------|
| in vitro      | CD19   | -                       | Leukemia, lymphoma | Cytotoxicity | [10]      |
| in vivo       | CD19   | Multiple doses 5 × 10^6; i.p. | lymphoma | Tumor growth inhibition | [11]      |
| in vitro      | CD19   | -                       | Leukemia, lymphoma | Degranulation and IFN-γ secretion | [12]      |
| in vivo and in vivo | CD37 | Multiple doses 10^7; intratumorally | Lymphoma | Cytotoxicity; tumor growth reduction | [13]      |
| in vivo       | Canine CD20-ζ | 2.4 × 10^6, 5.4 × 10^7, 1.1 × 10^6 cells i.v.; 1.16 × 10^6 cells i.n. | Lymphoma | Antitumor activity | [14]      |
| in vitro and in vivo | CD19 | 5 × 10^6, 1 × 10^7, or 2.5 × 10^7 cells; i.v. | Leukemia | Cytotoxicity | [15]      |
| in vivo       | CD19   | Multiple doses 1 × 10^7 or 2 × 10^7, 5 × 10^6 and 5 × 10^6; i.v. | Acute lymphoblastic leukemia | Increased cytotoxicity with split doses | [16]      |
| in vivo       | CD19   | 20 × 10^6 or 10 × 10^6; i.v. | Acute lymphoblastic leukemia | Abrogation of CD19-based cytotoxicity due to the presence of IgG1-CH2CH3 spacer in CAR construct | [17]      |
| in vivo       | CD19   | 2 × 10^7; i.v. | Acute lymphoblastic leukemia | Cytotoxicity | [23]      |
| in vitro and in vivo | CD33 | 5 × 10^6; i.v. | Acute myeloid leukemia | Cytotoxicity; tumor growth reduction | [21]      |
| in vivo       | CD123  | 1 × 10^7; i.v. | Acute myeloid leukemia | Cytotoxicity | [22]      |

3. Effect of IVT mRNA CAR T Cells in Preclinical Studies Related to Solid Malignancies

3.1. Mesothelioma and Colon Cancers

Mesothelioma is a type of malignant tumor that occurs in the tissues that line the heart, stomach or lungs. Mesothelin and fibroblast activation protein are the two identified TAAs in mesothelioma and malignant pleural mesothelioma [24], in which mesothelin is a widely studied antigen in IVT mRNA CAR T. Colon cancer is a type of malignant tumor occurring in the inner wall of the large intestine.
TAAs identified in colon and colorectal cancer include human epidermal growth factor receptor 2 (HER2), CEA, epithelial cell adhesion molecule (EpCAM) and human leukocyte antigen (HLA) [25]. Zhao et al. reported that repeated administration (intratumor) of mesothelin-targeting IVT mRNA CAR T cells markedly reduced flank mesothelioma tumors in a mouse model [26]. Moreover, the authors found similar protection in a mouse model of disseminated intraperitoneal tumors obtained from a malignant mesothelioma patient after injecting mesothelin-targeting IVT mRNA CAR T cells derived from the same patient, which suggested that autologous T cells may be redirected against TAAs through IVT mRNA.

Lehner et al. documented the cytolytic ability of mRNA-directed CAR T cells against natural killer group 2D receptor (NKG2D) in Ewing’s sarcoma family of tumors (ESFT) cell lines [27]. In this study, the authors observed that the expression of mRNA-coded NKG2D receptor lasted for few hours after transfection, while its expression was irreversibly reduced several hours after transfection, suggesting the controlled regulation of IVT NKG2D mRNA expression in T cells.

3.2. Ovarian and Breast Cancers

Ovarian and breast cancers are common in older women. TAAs identified in ovarian cancer include HER2, hepatocyte growth factor receptor (c-Met), mesothelin, folate receptor alpha (FRα), cancer/testis antigen 1B and cancer antigen 125 [24]. TAAs identified in breast cancer include HER2, CEA, hepatocyte growth factor receptor (c-Met), NKG2D and ErbB2+MUC1 [24,28]. In 2009, Yoon et al. documented the evidence that human peripheral blood lymphocytes (PBLs) transfected with mRNA against receptor tyrosine protein kinase Her-2/neu killed human ovarian cancer cell line SKOV3 in vitro [29]. The cell death was attributed to the secretion of type I proinflammatory cytokines such as IFN-γ, IL 8 and granulocyte–macrophage colony stimulating factor (GM-CSF), chiefly mediated by CD8+ T cells. The authors coined the receptor-inserted PBL as chimeric immune receptor-PBL. Moreover, a significant reduction in tumor growth was found in an in vivo model of a SKOV3 cell-induced humanized mouse xenograft model administered with chimeric immune receptor mRNA. Schutsky et al. demonstrated the anti-cancer ability of IVT mRNA CAR T cells against FRα, a protein that regulates cell growth, in ovarian cancer models [30]. In vitro systems, human FRα-directed IVT mRNA CAR T cells killed human ovarian cancer cell lines OVCAR3, A187 and SKOV3. In addition, FRα-targeted mRNA significantly inhibited the cancer cell growth in localized and disseminated murine models of ovarian cancer.

In another study, human mesothelin-targeted mRNA was introduced in human peripheral lymphocytes and investigated in human in vitro and murine in vivo cancer models, with designed to express human mesothelin [31]. The results showed that mesothelin-targeted IVT CAR lymphocytes exerted cytotoxicity in the human K562 erythroleukaemia cell line and in the murine ovarian cancer Defb29/Vegf-a-luc cell line. Moreover, mesothelin-targeted IVT CAR lymphocytes significantly inhibited tumor growth in an in vivo humanized murine ovarian cancer model engineered to express human mesothelin. Anti-EpCAM mRNA CAR T cells produced anti-cancer activity in murine xenograft models of peritoneal ovarian and colorectal cancers by delaying the progression of tumor growth [32]. Hepatocyte growth factor receptor (c-Met) is a widely expressed TAA in solid tumors. In a recent study, it was reported that c-Met IVT mRNA-expressing T cells suppressed tumor growth in a murine ovarian cancer model and elicited a marked cytotoxic effect in human breast cancer cell lines BT20 and TB129 [33].

3.3. Neuroblastoma and Glioblastoma Multiforme

Neuroblastoma and glioblastoma multiforme are the most common malignant tumors arising from the central nervous system. TAAs identified in neuroblastoma include disialoganglioside GD2 and L1 cell adhesion molecule (L1-CAM). TAAs identified in glioblastoma multiforme include variant III of the epidermal growth factor receptor, HER2, CD133 and B7-H3 [24,34]. Selective antigen-targeted mRNA-incorporated CAR lymphocytes significantly modulate tumor growth in neuroblastoma models.
Disialoganglioside GD2 is a potential tumor antigen expressed in human melanoma and neuroblastoma. Human GD2-targeted mRNA CAR T cells produced an anti-cancer effect in localized and disseminated murine neuroblastoma cancer models [35]. Intra-tumoral injection of GD2-IVT mRNA-targeted T cells rapidly killed the tumor cells; however, it was noticed that GD2 mRNA-targeted T cells were unable to reach the tumor site by intravenous injection and that multiple doses of GD2 mRNA-targeted T cells delayed only the tumor outgrowth and did not remove the disseminated neuroblastoma cells, suggesting the importance of preserving CAR surface expression on the periphery until reaching the tumor site and eliciting a cytotoxic response.

Caruso et al. demonstrated the cytolytic efficacy of anti-EGFR-targeted mRNA CAR T cells (human) against human glioblastoma cell lines U87, T98G and LN18 [36].

### 3.4. Melanoma

Melanoma is a malignant form of skin cancer. TAAs identified in melanoma include vascular endothelial growth factor receptor 2 (VEGFR2), gp100, TRP-1, TRP-2, GD2, L1-CAM, cancer/testis antigen 1B and melanoma-associated chondroitin sulfate proteoglycan (MCSP; also referred to as chondroitin sulfate proteoglycan 4 (CSPG4)) [24,37]. Human T cells constructed with IVT mRNA against MCSP revealed considerable antitumor effects against in vitro A375M and Melur melanoma cell lines and in an in vivo murine melanoma model [38]. The study also reported antigen-specific elevated proinflammatory cytokines in MCSP IVT mRNA CAR T cells in response to tumor cells. Similar anti-melanoma cancer activity was exerted by human T cells, including peripheral blood mononuclear cells, CD8+ T cells and γ/δ T cells, transfected with mRNA specific to either gp100/HLA-A2-TCRs or MCSP CARs against human melanoma cell lines A375M and Mel526, and the lymphoma cell line Daudi [39]. Among other T cells, γ/δ T cells exerted cytotoxicity against melanoma cell lines despite secreting a low level of cytokines compared to other T cells investigated in the study, suggesting that γ/δ T cells are a promising and potentially safer T cell population to be used in CAR T therapy for melanoma.

In another study, human T cells were designed to express both gp100 TCRs and MCSP CARs using mRNA transfection and tested against A375M and Mel526 cell lines [40]. The authors of the study coined those T cells as T cells expressing two additional receptors (TETARs). Antigen-specific synthesis of IFN-γ, TNF and IL-2 cytokines were noticed in TETARS, which induced cell death in melanoma cell lines. In continuation of the above study, the same group constructed TETARS using combined DNA-based TCRs for gp100 (via lentiviral transduction) and mRNA-based CARs against CSPG4 and investigated the antitumor effect in the A375M cell line [41]. Both TCRs and CARs were expressed in T cells which killed A375M cells by antigen-based proinflammatory cytokines. Clinical-scale production of mRNA IVT CAR T cells redirected against melanoma-targeted CSPG4 was reported [42]. Moreover, the same group studied the efficacy of mRNA CARs expressed in natural killer T (NKT) cells against a melanoma cell line [43]. CSPG4-directed mRNA CARs were transfected in human NKT cells and cytotoxicity was evaluated in the A375M cell line. The results showed that CSPG4 CAR-directed NKT cells secreted proinflammatory IL-2, TNF-α and IFN-γ cytokines after recognizing specific antigens in the A375M cell line and thus induced cell death. Walseng et al. manufactured TCR-based CAR T cells and NK cell line NK-92 and studied the potential of therapeutic TCRs in NK cells [44]. It is imperative to mention here that unlike CARs, which are limited to detecting the surface antigens, TCRs can also recognize intracellular epitopes present in major histocompatibility complex (MHC) molecules. However, TCR activation depends on the signaling proteins present in the CD3 complex, which is restricted to T cells. Consequently, there might be competition between exogenous and endogenous TCRs to utilize the signaling proteins. Moreover, mispairing between TCRs may occur. In order to minimize these risks, a TCR-CAR construct was made by linking a single-chain soluble TCR with the transmembrane and signaling domains of a CAR construct. The results showed that the IVT mRNA TCR-CAR construct was able to conserve the specificity of the original TCR and was independent of the signaling molecules of the endogenous TCR. Moreover, a TCR-CAR-redirected
NK-92 cell line induced cytotoxicity in tumor cells, suggesting the possibility to manufacture NK cells with the heterogeneous target recognition of TCRs.

Inoo et al. reported the antitumor effect of anti-VEGFR2 IVT mRNA CAR T cells in a murine melanoma model [45]. Antigen-specific cytokine release was noticed in anti-VEGFR2 mRNA CAR T cells, which triggered cytotoxic events in cancer cells and suppressed tumor growth.

Taken together, a substantial number of preclinical studies have been reported in hematologic and solid malignancies with IVT mRNA CAR T.

An overview of the results obtained in preclinical studies related to solid malignancies is shown in Table 2.

Table 2. Preclinical studies regarding the effects of IVT mRNA CAR T cells in solid malignancies (i.p., intraperitoneal; i.v., intravenous).

| Type of Study | Target | Dose and Administration | Tumor Type | Results | Reference |
|---------------|--------|-------------------------|------------|---------|-----------|
| in vivo       | Mesothelin | 10–15 × 10⁶; intratumorally | Mesothelioma | Tumor growth reduction | [26] |
| in vitro      | NKG2D  | -                       | Ewing’s sarcoma family of tumors | Short-lived expression of mRNA | [27] |
| in vitro and in vivo | Her2 | 5 × 10⁶; intratumorally or i.p. | Ovarian cancer | Cytotoxicity; tumor growth reduction | [29] |
| in vitro and in vivo | FRα | Multiple doses 10⁶; i.p. | Ovarian cancer | Tumor growth inhibition | [30] |
| in vitro and in vivo | Epithelial cell adhesion molecule | 1 × 10⁷ or 1 × 10⁷; i.p. | Ovarian cancer | Tumor growth inhibition | [31] |
| in vivo       | c-Met  | 2 × 10⁷; i.p. | Breast and ovarian cancer | Cytotoxicity; tumor growth inhibition | [33] |
| in vivo       | Disialoganglioside GD2 | 5 × 10⁶; intratumorally | Neuroblastoma | Cytotoxicity | [35] |
| in vitro      | EGFR   | -                       | Glioblastoma | Cytotoxicity | [36] |
| in vitro and in vivo | gp100/HLA-A2 or M-CSF | - | Melanoma | Cytotoxicity | [39] |
| in vitro      | gp100 and M-CSF | - | Melanoma | Cytotoxicity | [40] |
| in vitro      | CSF-1R | -                       | Melanoma | Cytotoxicity | [43] |
| in vivo       | VEGFR2 | 5 × 10⁶; i.v. | Melanoma | Tumor growth reduction | [45] |

4. IVT mRNA-Based Clinical Trials in Hematologic and Solid Tumors

Clinical trials using IVT mRNA CAR T for hematologic and solid tumors have been initiated worldwide. Trials with anti-mesothelin CARs and anti-cMet CARs against malignant pleural mesothelioma (NCT01355965), metastatic pancreatic ductal adenocarcinoma (NCT01897415) and metastatic triple-negative breast cancer (NCT01837602) have been completed. A few of the ongoing clinical trials are studying the therapeutic effect of anti-cMet CARs, anti-CD19 CARs and anti-CD20 CARs against malignant melanoma breast cancer (NCT03060356), Hodgkin’s lymphoma (NCT02624258), B cell leukemia B cell lymphoma (NCT03166878) and non-Hodgkin’s lymphoma B cell chronic lymphocytic leukemia (NCT02315118). In a pilot clinical trial, CAR T cells reprogrammed with mRNA that targeted CD123 were tested in relapsed/refractory acute myeloid leukemia patients [46]. Although the method was safe, no antitumor effect was elicited by CAR T cells. Moreover, the study reported a poor quality of T cells from the patients and a lack of persistence of administered CAR T cells. In 2018, Svoboda et al. reported the transient responses of CD19-targeted mRNA engineered T cells (CD19 CAR T) in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL). This lymphoma is characterized by scant CD19+Hodgkin and Reed-Sternberg (HRS) cells within an
immunosuppressive tumor microenvironment which causes limitations for cellular therapies directly targeting antigens expressed on HRS cells [47]. In this trial, the CD19 antigen was targeted against CD19+ B cells present in the tumor microenvironment and putative circulating CD19+HRS cells, which may result in the disruption of the tumor microenvironment necessary for the survival of HRS cells. Four patients were administered CD19 CART cells and obtained transient responses; one patient achieved a complete response and one patient achieved a partial response. Two patients showed no responses and this resulted in progressive disease and stable disease outcomes. All of them were shown to have no severe toxicity owing to the transient expression of the inserted CAR mRNA of the T cells.

Phase I clinical trials have been initiated to investigate the efficacy of these IVT CAR T cells redirected for mesothelin (CARTmeso cells) in malignant pleural mesothelioma patients and other tumors that overexpress mesothelin [48]. During the trial, severe anaphylaxis was observed in one patient, which was attributed to the sudden rise in immunoglobulin G (IgG) after two initial injections. Anaphylaxis may also result from an IgE-driven immune response to foreign CAR moieties that degranulate mast cells [49] and that multiple doses of CAR T cells may contribute to anaphylaxis reactions [48]. Consequently, the dosage schema was modified, followed by the absence of anaphylaxis. In a follow-up study, two of these patients showed partial antitumor responses as evidenced by the presence of novel circulating antitumor antibodies and tumor regression with a lack of apparent on-target off-tumor side effects in normal cells [50]. In another phase I clinical trial with six pancreatic ductal adenocarcinoma patients, CARTmeso cell treatment resulted in an elevated level of circulating antibodies produced against protumor-related proteins such as B cell maturation antigen, Ras-related protein Rab-11B, signal-transducing adaptor protein 1, programmed cell death protein 1 (PD1), programmed death ligand 1 (PD1L), and transducin-like enhancer protein 3 in one patient [51]. Tchou et al. reported that no side effect was noticed in metastatic breast cancer patients who intratumorally received c-Met IVT mRNA CAR T cells in a phase 0 clinical trial. Interestingly, immunohistochemical analysis from excised tumors displayed a high degree of necrosis, suggesting the anti-cancer effect of c-Met IVT mRNA CAR T cells in breast cancer patients [33]. A few more clinical trials are ongoing with breast cancer and colorectal cancer patients; however, no clinical updates have been provided.

An overview of the results obtained in clinical trials related to solid and hematologic malignancies is shown in Table 3.

**Table 3.** Clinical trials regarding the effects of IVT mRNA CAR T cells in hematologic and solid malignancies (i.v., intravenous).

| Phase     | National Clinical Trial (NCT) No. | Target      | Dose and Administration | Tumor Type                      | Results                                           | Reference |
|-----------|----------------------------------|-------------|--------------------------|---------------------------------|--------------------------------------------------|-----------|
| Early Phase 1 | NCT02623582                      | CD123       | 3 or 6 doses 4 × 10^6 cells/kg; i.v. | Relapsed/refractory acute myeloid leukemia | Safe method; no antitumor effects [46]           |           |
| Early Phase 1 | NCT02277522 (adult); NCT02624258 (pediatric) | CD19 | 6 doses in the range 7.46 × 10^5–2.11 × 10^6 cells/kg; i.v. | Hodgkin’s lymphoma | No severe toxicity [47]                           |           |
| Phase 1   | NCT01355965                      | Mesothelin  | Cohort 1: 1 × 10^9 and 1 × 10^10; Extended cohort: 3 doses of 1 × 10^8 cells followed by 3 doses of 1 × 10^9; i.v. | Malignant pleural mesothelioma | Severe anaphylaxis in one patient; partial antitumor response [48,50] |           |
| Phase 1   | NCT01897415                      | Mesothelin  | 3 doses weekly 1–3 × 10^9/10^8/m^2; i.v. | Metastatic pancreatic ductal adenocarcinoma | Increased expression of antitumor antibodies [51] |           |
| Phase 0   | NCT01837602                      | c-Met       | 3 × 10^7 or 3 × 10^8 cells/intratumoral | Metastatic breast cancer | Anti-cancer effects [33]                         |           |
5. Future Directions

A considerable number of preclinical studies have reported the promising and safer therapeutic ability of IVT mRNA CAR T cells in hematologic and solid tumors. Given the promising preclinical results from IVT mRNA CAR T cells, more clinical trials are warranted to investigate the therapeutic efficacy of mRNA-redirected CAR T cells in different cancers. To achieve this translational part, additional preclinical studies are required to study the cytotoxic and tumor-reducing efficacies of new mRNA-engineered CAR constructs manufactured against novel protumor antigens and to elicit the antitumor response via intravenous injections. In addition, future studies are warranted to circumvent the lack of sustainable function and potency associated with IVT mRNA. Foster et al. purified mRNA using recent RNA technology by inserting a modified 1-methylpseudouridin nucleoside into the mRNA to avoid immune stimulation and purified it of possible double-stranded RNA contaminants, which may halt the translation, with the help of RNase III [23]. Human CAR T cells engineered with purified CD19 mRNA exerted a twofold increase in cytotoxicity towards the Nalm-6 cell line and a 100-fold inhibition of leukemia burden in humanized ALL mice with enhanced persistence. More animal studies designed to investigate the purity level of mRNA required before transfection and to study the potential of re-constructed mRNA in T cells against tumor-specific antigens together with cytokine stimulatory signals are warranted, which might increase the number of clinical trials on IVT mRNA CART therapy in hematologic and solid tumors in the future. Last, but not least, more studies should focus on improving the homing of mRNA CAR T cells into the tumor microenvironment by neutralizing the localized immunosuppressive cues.

6. Conclusions

IVT mRNA CAR T cell therapy, a form of adoptive T cell therapy, has received significant attention due to its ability to drive away the tumor immune response from the on-target off-tumor phenomenon in hematologic and solid tumors. Preclinical studies have demonstrated the efficacy of these transiently redirected T cells in different hematologic and solid tumor models. Selective antigen-specific proinflammatory cytokine secretion, cell death induction, tumor growth reduction and prolonged survival are the key results from in vitro and in vivo studies. Limited clinical trials have reported positive responses for IVT mRNA CAR T cell therapy in the management of hematologic and solid tumors. Additional clinical trials with large sets of patients are warranted to test the therapeutic efficacy of IVT mRNA CAR T cells in hematologic and solid malignancies.

Author Contributions: Conceptualization, T.S.R., P.B. and E.M.; investigation, T.S.R. and A.G.; writing—original draft preparation, T.S.R. All authors have read and agreed to the published version of the manuscript.

Funding: The present article was supported by DST-FIST to the Department of Biotechnology, Karpagam Academy of Higher Education (SR/FST/LS-1/2018/187; dated 26 December 2018) and current research funds 2020, Ministry of Health, of IRCCS-Centro Neurolesi “Bonino-Pulejo”, Messina, Italy.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Abbreviations

CAR T  Chimeric antigen receptor T cell
IVT mRNA CAR T  in vitro transcribed anti-mRNA-based CAR T cells
TCR  T cell receptor
CAR  Chimeric antigen receptor
scFv  Single-chain variable fragment
TAA  Tumor-associated antigen
EGFR  Epidermal growth factor receptor
CEA  Carcinoembryonic antigen
ERBB2  Epidermal growth factor receptor 2
PSMA  Prostate-specific membrane antigen
B-CLL  B cell chronic lymphocytic leukemia
B-NHL  B cell non-Hodgkin’s lymphoma
FcγR  Fragment c gamma receptor
BiTEs  Bispecific T cell engager
AML  Acute myeloid leukemia
NKG2D  Natural killer group 2D
ESFT  Ewing’s sarcoma family of tumors
TGFβRIImut  Transforming growth factor β receptor II frameshift mutation
GM-CSF  Granulocyte–macrophage colony Stimulating factor
FRα  Folate receptor alpha
EpCAM  Epithelial cell adhesion molecule
GBM  Glioblastoma multiforme
gp100  Glycoprotein 100
TRP-1  Tyrosinase-related protein 1
TRP-2  Tyrosinase-related protein 2
GD2  Disialoganglioside 2
L1-CAM  L1 cell adhesion molecule
MCSP  Melanoma-associated chondroitin sulfate proteoglycan
TETARs  T cells expressing two additional receptors
CSPG4  Chondroitin sulfate proteoglycan 4
NKT  Natural killer T
VEGFR2  Vascular endothelial growth factor receptor 2
CARTmeso cells  CAR T cells redirected for mesothelin
IgG  Immunoglobulin G
PD1  Programmed cell death protein 1
PDL1  Programmed death ligand 1

References

1. Cheadle, E.J.; Gornall, H.; Baldan, V.; Hanson, V.; Hawkins, R.E.; Gilham, D.E. CAR T cells: Driving the road from the laboratory to the clinic. Immunol. Rev. 2014, 257, 91–106. [CrossRef] [PubMed]
2. Sharpe, M.; Mount, N. Genetically modified T cells in cancer therapy: Opportunities and challenges. Dis. Models Mech. 2015, 8, 337–350. [CrossRef] [PubMed]
3. Newick, K.; O’Brien, S.; Moon, E.; Albelda, S.M. CAR T Cell Therapy for Solid Tumors. Annu. Rev. Med. 2017, 68, 139–152. [CrossRef] [PubMed]
4. Garber, K. Driving T-cell immunotherapy to solid tumors. Nat. Biotechnol. 2018, 36, 215–219. [CrossRef] [PubMed]
5. Kenderian, S.S.; Porter, D.L.; Gill, S. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol. Blood Marrow Transplant. 2017, 23, 235–246. [CrossRef]
6. Martinez, M.; Moon, E.K. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol. 2019, 10, 128. [CrossRef]
7. Zhang, Q.; Ping, J.; Huang, Z.; Zhang, X.; Zhou, J.; Wang, G.; Liu, S.; Ma, J. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. J. Immunol. Res. 2020, 2020, 1924379. [CrossRef]
8. Miliotou, A.N.; Papadopoulou, L.C. In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development. Methods Mol. Biol. 2020, 2086, 87–117. [CrossRef]
9. Braun, D.A.; Wu, C.J. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J. 2017, 23, 115–124. [CrossRef]
10. Rabinovich, P.M.; Komarovskaya, M.E.; Ye, Z.J.; Imai, C.; Campana, D.; Bahceci, E.; Weissman, S.M. Synthetic messenger RNA as a tool for gene therapy. *Hum. Gene Ther.* 2006, 17, 1027–1035. [CrossRef]

11. Rabinovich, P.M.; Komarovskaya, M.E.; Wrzesinski, S.H.; Alderman, J.L.; Budak-Alpdogan, T.; Karpikov, A.; Guo, H.E.; Flavell, R.A.; Cheung, N.K.; Weissman, S.M.; et al. Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes. *Hum. Gene Ther.* 2009, 20, 51–61. [CrossRef] [PubMed]

12. Almasbak, H.; Rian, E.; Hoel, H.J.; Pule, M.; Walchli, S.; Kvalheim, G.; Gaudernack, G.; Rasmussen, A.M. Transiently redirected T cells for adoptive transfer. *Cytotherapy* 2011, 13, 629–640. [CrossRef] [PubMed]

13. Koksal, H.; Dillard, P.; Josellsson, S.E.; Maggardottir, S.M.; Pollmann, S.; Fane, A.; Blaker, Y.N.; Beiske, K.; Huse, K.; Kolstad, A.; et al. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. *Blood Adv.* 2019, 3, 1230–1243. [CrossRef] [PubMed]

14. Panjwani, M.K.; Smith, J.B.; Schutsky, K.; Gnanandarajah, J.; O’Connor, C.M.; Powell, D.J., Jr.; Mason, N.J. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. *Mol. Ther. J. Am. Soc. Gene Ther.* 2016, 24, 1602–1614. [CrossRef] [PubMed]

15. Barrett, D.M.; Zhao, Y.; Liu, X.; Jiang, S.; Carpenito, C.; Kalos, M.; Carroll, R.G.; June, C.H.; Grupp, S.A. Treatment of advanced leukemia in mice with mRNA engineered T cells. *Hum. Gene Ther.* 2011, 22, 1575–1586. [CrossRef]

16. Barrett, D.M.; Liu, X.; Jiang, S.; June, C.H.; Grupp, S.A.; Zhao, Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. *Hum. Gene Ther.* 2013, 24, 717–727. [CrossRef]

17. Almasbak, H.; Walseng, E.; Kristian, A.; Myhre, M.R.; Suso, E.M.; Munthe, L.A.; Andersen, J.T.; Wang, M.Y.; Kvalheim, G.; Gaudernack, G.; et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. *Hum. Gene Ther.* 2015, 22, 391–403. [CrossRef]

18. Hudecek, M.; Sommermeyer, D.; Kosasih, P.L.; Silva-Benedict, A.; Liu, L.; Rader, C.; Jensen, M.C.; Riddell, S.R. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunol. Res.* 2015, 3, 125–135. [CrossRef]

19. Till, B.G.; Jensen, M.C.; Wang, J.; Qian, X.; Gopal, A.K.; Maloney, D.G.; Lindgren, C.G.; Lin, Y.; Pagel, J.M.; Budde, L.E.; et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. *Blood* 2012, 119, 3940–3950. [CrossRef]

20. Al-Hussaini, M.; Retig, M.P.; Ritchey, J.K.; Karpova, D.; Uy, G.L.; Eisenberg, L.G.; Gao, F.; Eades, W.C.; Bonvini, E.; Chichili, G.R.; et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. *Blood* 2016, 127, 122–131. [CrossRef]

21. Kenderian, S.S.; Ruella, M.; Shestova, O.; Klichinsky, M.; Aikawa, V.; Morrissette, J.J.D.; Scholler, J.; Song, D.; Porter, D.J.; Carroll, M.; et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. *Leukemia* 2015, 29, 1637–1647. [CrossRef] [PubMed]

22. Tassin, S.K.; Kenderian, S.S.; Shen, F.; Ruella, M.; Shestova, O.; Kozlowski, M.; Li, Y.; Schrank-Hacker, A.; Morrissette, J.J.D.; Carroll, M.; et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood* 2017, 129, 2395–2407. [CrossRef] [PubMed]

23. Foster, J.B.; Choudhari, N.; Perazzelli, J.; Sorm, J.; Hofmann, T.J.; Jain, P.; Storm, P.B.; Pardi, N.; Weissman, D.; Waanders, A.J.; et al. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. *Hum. Gene Ther.* 2019, 30, 168–178. [CrossRef] [PubMed]

24. Yu, S.; Li, A.; Liu, Q.; Li, T.; Yuan, X.; Han, X.; Wu, K. Chimeric antigen receptor T cells: A novel therapy for solid tumors. *J. Hematol. Oncol.* 2017, 10, 78. [CrossRef]

25. Wagner, S.; Mullins, C.S.; Linnebacher, M. Colorectal cancer vaccines: Tumor-associated antigens vs. neoantigens. *World J. Gastroenterol.* 2018, 24, 5418–5432. [CrossRef]

26. Zhao, Y.B.; Moon, E.; Carpenito, C.; Paulos, C.M.; Liu, X.J.; Brennan, A.L.; Chew, A.; Carroll, R.G.; Scholler, J.; Levine, B.L.; et al. Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. *Cancer Res.* 2010, 70, 9053–9061. [CrossRef]

27. Lehner, M.; Gotz, G.; Proff, J.; Schaft, N.; Dorrie, J.; Full, F.; Ensser, A.; Muller, Y.A.; Cervenka, A.; Abken, H.; et al. Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. *PLoS ONE* 2012, 7, e31210. [CrossRef]

28. Mirzaei, H.R.; Rodriguez, A.; Shephpird, J.; Brown, C.E.; Badie, B. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. *Front. Immunol.* 2017, 8, 1850. [CrossRef]
29. Yoon, S.H.; Lee, J.M.; Cho, H.I.; Kim, E.K.; Kim, H.S.; Park, M.Y.; Kim, T.G. Adoptive immunotherapy using human peripheral blood lymphocytes transfected with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. *Cancer Gene Ther.* **2009**, *16*, 489–497. [CrossRef]
30. Schustky, K.; Song, D.G.; Lynn, R.; Smith, J.B.; Poussin, M.; Figini, M.; Zhao, Y.B.; Powell, D.J. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. *Oncotarget* **2015**, *6*, 28911–28928. [CrossRef]
31. Hung, C.F.; Xu, X.Q.; Li, L.H.; Ma, Y.; Jin, Q.; Viley, A.; Allen, C.; Natarajan, P.; Shivakumar, R.; Peshwa, M.V.; et al. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. *Hum. Gene Ther.* **2018**, *29*, 614–625. [CrossRef] [PubMed]
32. Ang, W.X.; Li, Z.D.; Chi, Z.X.; Du, S.H.; Chen, C.; Tay, J.C.K.; Toh, H.C.; Connolly, J.E.; Xu, X.H.; Wang, S. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. *Oncotarget* **2017**, *8*, 13345–13359. [CrossRef] [PubMed]
33. Tchou, J.; Zhao, Y.B.; Levine, B.L.; Zhang, P.J.; Davis, M.M.; Melenhorst, J.J.; Kulikovskaya, I.; Brennan, A.L.; Liu, X.J.; Lacey, S.F.; et al. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunol. Res.* **2017**, *5*, 1152–1161. [CrossRef] [PubMed]
34. Tang, X.; Zhao, S.; Zhang, Y.; Wang, Y.; Zhang, Z.; Yang, M.; Zhu, Y.; Zhang, G.; Guo, G.; Tong, A.; et al. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. *Mol. Ther. Oncolytics* **2019**, *14*, 279–287. [CrossRef]
35. Singh, N.; Liu, X.; Hulitt, J.; Jiang, S.; June, C.H.; Grupp, S.A.; Barrett, D.M.; Zhao, Y. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunol. Res.* **2014**, *2*, 1059–1070. [CrossRef]
36. Caruso, H.G.; Torikai, H.; Zhang, L.; Matti, S.; Dai, J.L.; Do, K.A.; Singh, H.; Huls, H.; Lee, D.A.; Champlin, R.E.; et al. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. *J. Immunother.* **2016**, *39*, 205–217. [CrossRef]
37. Ilieva, K.M.; Cheung, A.; Mele, S.; Chiariuttini, G.; Crescioli, S.; Griffin, M.; Nakamura, M.; Spicer, J.F.; Tsoka, S.; Lacy, K.E.; et al. Chondroitin Sulfate Proteoglycan 4 and Its Potential as an Antibody Immunotherapeutic Target across Different Tumor Types. *Front. Immunol.* **2017**, *8*, 111. [CrossRef]
38. Krug, C.; Birkholz, K.; Paulus, A.; Schwenkert, M.; Schmidt, P.; Hoffmann, N.; Hombach, A.; Fey, G.; Abken, H.; Schuler, G.; et al. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. *Cancer Immunol. Immun.* **2015**, *64*, 1623–1635. [CrossRef]
39. Harrer, D.C.; Simon, B.; Fuji, S.I.; Shimizu, K.; Uslu, U.; Schuler, G.; Gerer, K.F.; Hoyer, S.; Dorrie, J.; Schaft, N. RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: A safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma. *BMC Cancer* **2017**, *17*, 551. [CrossRef]
40. Uslu, U.; Schuler, G.; Dorrie, J.; Schaft, N. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma. *Exp. Dermatol.* **2016**, *25*, 872–879. [CrossRef]
41. Simon, B.; Harrer, D.C.; Schuler-Thurner, B.; Schuler, G.; Uslu, A. Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer. *Cancers* **2019**, *11*, 696. [CrossRef] [PubMed]
42. Wiesinger, M.; Marz, J.; Kummer, M.; Schuler, G.; Dorrie, J.; Schuler-Thurner, B.; Schaft, N. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. *Cancers* **2019**, *11*, 1198. [CrossRef] [PubMed]
43. Simon, B.; Wiesinger, M.; Marz, J.; Wistuba-Hamprecht, K.; Weide, B.; Schuler-Thurner, B.; Schuler, G.; Dorrie, J.; Uslu, U. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma. *Int. J. Mol. Sci.* **2018**, *19*, 2365. [CrossRef] [PubMed]
44. Walseng, E.; Koksal, H.; Sektoglu, I.M.; Fane, A.; Skorstad, G.; Kvalheim, G.; Gaudernack, G.; Inderberg, E.M.; Walchi, S. A TCR-based Chimeric Antigen Receptor. *Sci. Rep.* **2017**, *7*, 10713. [CrossRef] [PubMed]
45. Inoo, K.; Inagaki, R.; Fujiwara, K.; Sasawatari, S.; Kamigaki, T.; Nakagawa, S.; Okada, N. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. *Mol. Ther. Oncolytics* **2016**, *3*. [CrossRef] [PubMed]
46. Cummins, K.D.; Frey, N.; Nelson, A.M.; Schmidt, A.; Luger, S.; Isaacs, R.E.; Lacey, S.F.; Hexner, E.; Melenhorst, J.J.; June, C.H.; et al. Treating Relapsed/Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. *Blood* 2017, 130, 1359.

47. Svoboda, J.; Rheingold, S.R.; Gill, S.I.; Grupp, S.A.; Lacey, S.F.; Kulikovskaya, I.; Suhoski, M.M.; Melenhorst, J.J.; Loudon, B.; Mato, A.R.; et al. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. *Blood* 2018, 132, 1022–1026. [CrossRef]

48. Maus, M.V.; Haas, A.R.; Beatty, G.L.; Albelda, S.M.; Levine, B.L.; Liu, X.J.; Zhao, Y.B.; Kalos, M.; June, C.H. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans. *Cancer Immunol. Res.* 2013, 1, 26–31. [CrossRef]

49. Caruso, H.G.; Heimberger, A.B.; Cooper, L.J.N. Steering CAR T cells to distinguish friend from foe. *Oncoimmunology* 2019, 8, e1271857. [CrossRef]

50. Beatty, G.L.; Haas, A.R.; Maus, M.V.; Torigian, D.A.; Soulen, M.C.; Plesa, G.; Chew, A.; Zhao, Y.; Levine, B.L.; Albelda, S.M.; et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunol. Res.* 2014, 2, 112–120. [CrossRef]

51. Beatty, G.L.; O’Hara, M.H.; Lacey, S.F.; Torigian, D.A.; Nazimuddin, F.; Chen, F.; Kulikovskaya, I.M.; Soulen, M.C.; McGarvey, M.; Nelson, A.M.; et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology* 2018, 155, 29–32. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).